

A David Paltiel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4722982/publications.pdf>

Version: 2024-02-01

161
papers

9,975
citations

47006

47
h-index

39675

94
g-index

169
all docs

169
docs citations

169
times ranked

11832
citing authors

#	ARTICLE	IF	CITATIONS
1	Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States. <i>Arthritis Care and Research</i> , 2022, 74, 1349-1358.	3.4	12
2	Reducing the Prevalence of Alcohol-Exposed Pregnancies in the United States: A Simulation Modeling Study. <i>Medical Decision Making</i> , 2022, 42, 217-227.	2.4	4
3	Adventures in COVID-19 Policy Modeling: Education Edition. <i>Current HIV/AIDS Reports</i> , 2022, 19, 94-100.	3.1	4
4	Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States. <i>Annals of Internal Medicine</i> , 2022, 175, 479-489.	3.9	37
5	Reliability of patient self-reports to clinician-assigned functional scores of inclusion body myositis. <i>Journal of the Neurological Sciences</i> , 2022, 436, 120228.	0.6	0
6	Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, e1927-e1935.	5.8	7
7	Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach. <i>Gut</i> , 2021, 70, 1561-1569.	12.1	7
8	Has depression surpassed HIV as a burden to gay and bisexual men's health in the United States? A comparative modeling study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 273-282.	3.1	7
9	Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic. <i>Medical Decision Making</i> , 2021, 41, 386-392.	2.4	7
10	Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. <i>Annals of Internal Medicine</i> , 2021, 174, 803-810.	3.9	43
11	The Dynamics of Infectious Diseases Associated With Injection Drug Use in Lawrence and Lowell, Massachusetts. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab128.	0.9	9
12	The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m ² or Greater. <i>Annals of Internal Medicine</i> , 2021, 174, 747-757.	3.9	17
13	Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment. <i>Annals of Internal Medicine</i> , 2021, 174, 568-570.	3.9	60
14	Maximizing the Efficiency of Active Case Finding for SARS-CoV-2 Using Bandit Algorithms. <i>Medical Decision Making</i> , 2021, 41, 970-977.	2.4	4
15	Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021. <i>Annals of Internal Medicine</i> , 2021, 174, 1563-1571.	3.9	23
16	Responding to SARS-CoV-2 on College Campuses—Only Beginning to Understand What Works and Why. <i>JAMA Network Open</i> , 2021, 4, e2138904.	5.9	1
17	COVID-19 Testing and Case Rates and Social Contact Among Residential College Students in Connecticut During the 2020-2021 Academic Year. <i>JAMA Network Open</i> , 2021, 4, e2140602.	5.9	22
18	The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. <i>Clinical Infectious Diseases</i> , 2020, 70, 633-642.	5.8	20

#	ARTICLE	IF	CITATIONS
19	Quality-Adjusted Life-Years Lost Due to Physical Inactivity in a US Population With Osteoarthritis. <i>Arthritis Care and Research</i> , 2020, 72, 1349-1357.	3.4	21
20	Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. <i>Addiction</i> , 2020, 115, 437-450.	3.3	15
21	Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis. <i>Annals of Internal Medicine</i> , 2020, 173, 507-508.	3.9	4
22	Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis. <i>Annals of Internal Medicine</i> , 2020, 172, 583-590.	3.9	40
23	Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States. <i>JAMA Network Open</i> , 2020, 3, e2016818.	5.9	425
24	Novel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population. <i>BMJ Open</i> , 2020, 10, e032579.	1.9	7
25	Waiting for Certainty on Covid-19 Antibody Tests - At What Cost?. <i>New England Journal of Medicine</i> , 2020, 383, e37.	27.0	80
26	Has Pre-exposure Prophylaxis Made a Difference at a Population Level? Jury Is Still Out. <i>Clinical Infectious Diseases</i> , 2020, 71, 3152-3153.	5.8	8
27	Budget Impact of Funding an Intensive Diet and Exercise Program for Overweight and Obese Patients With Knee Osteoarthritis. <i>ACR Open Rheumatology</i> , 2020, 2, 26-36.	2.1	6
28	Cost-effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. <i>Arthritis Care and Research</i> , 2019, 71, 855-864.	3.4	31
29	Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Cote d'Ivoire: A model-based analysis. <i>PLoS ONE</i> , 2019, 14, e0219068.	2.5	5
30	Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector. <i>PLoS ONE</i> , 2019, 14, e0218890.	2.5	37
31	A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management. <i>Value in Health</i> , 2019, 22, 1102-1110.	0.3	12
32	Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 728-739.	9.1	54
33	New USPSTF Guidelines for HIV Screening and Preexposure Prophylaxis (PrEP). <i>JAMA Network Open</i> , 2019, 2, e195042.	5.9	10
34	An Adaptive Approach to Locating Mobile HIV Testing Services. <i>Medical Decision Making</i> , 2018, 38, 262-272.	2.4	6
35	The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. <i>Journal of the International AIDS Society</i> , 2018, 21, e25085.	3.0	17
36	The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. <i>Journal of the International AIDS Society</i> , 2018, 21, e25096.	3.0	24

#	ARTICLE	IF	CITATIONS
37	2000. Rapid, Point-of-care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-Effectiveness and Budgetary Impact Analysis for India's Public Sector. <i>Open Forum Infectious Diseases</i> , 2018, 5, S582-S582.	0.9	0
38	Bayesian adaptive algorithms for locating HIV mobile testing services. <i>BMC Medicine</i> , 2018, 16, 155.	5.5	9
39	Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis. <i>Arthritis Care and Research</i> , 2017, 69, 234-242.	3.4	30
40	A Flow-Based Model of the HIV Care Continuum in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 548-553.	2.1	20
41	Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. <i>Vaccine</i> , 2017, 35, 3506-3514.	3.8	53
42	Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. <i>JAMA Internal Medicine</i> , 2017, 177, 1613.	5.1	99
43	Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. <i>Annals of Internal Medicine</i> , 2017, 167, 618.	3.9	18
44	Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx081.	0.9	5
45	The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. <i>Journal of Infectious Diseases</i> , 2017, 216, 798-807.	4.0	22
46	Survival benefits of antiretroviral therapy in Brazil: a model-based analysis. <i>Journal of the International AIDS Society</i> , 2016, 19, 20623.	3.0	19
47	The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa. <i>Annals of Internal Medicine</i> , 2016, 165, 325.	3.9	36
48	Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 1523-1531.	4.0	39
49	Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2016, 283, 20161211.	2.6	10
50	Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 1672-1681.	4.0	93
51	The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. <i>Clinical Infectious Diseases</i> , 2016, 62, 784-791.	5.8	50
52	The Epi-TAF for Tenofovir Disoproxil Fumarate?: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 62, 915-918.	5.8	19
53	Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. <i>Clinical Infectious Diseases</i> , 2016, 62, 1454-1462.	5.8	14
54	Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. <i>PLoS ONE</i> , 2016, 11, e0165614.	2.5	20

#	ARTICLE	IF	CITATIONS
55	Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. <i>HIV Clinical Trials</i> , 2015, 16, 207-218.	2.0	4
56	Lifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty. <i>Arthritis Care and Research</i> , 2015, 67, 203-215.	3.4	279
57	Demographic and clinical features of inclusion body myositis in north America. <i>Muscle and Nerve</i> , 2015, 52, 527-533.	2.2	27
58	The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2015, 60, 1102-1110.	5.8	41
59	Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 152-161.	2.1	11
60	The Lifetime Medical Cost Savings From Preventing HIV in the United States. <i>Medical Care</i> , 2015, 53, 293-301.	2.4	94
61	Reducing Sexual Violence by Increasing the Supply of Toilets in Khayelitsha, South Africa: A Mathematical Model. <i>PLoS ONE</i> , 2015, 10, e0122244.	2.5	26
62	Defining the Value of Future Research to Identify the Preferred Treatment of Meniscal Tear in the Presence of Knee Osteoarthritis. <i>PLoS ONE</i> , 2015, 10, e0130256.	2.5	16
63	Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness. <i>PLoS ONE</i> , 2014, 9, e85197.	2.5	45
64	Misinterpretation of HIV Preexposure Prophylaxis Findings. <i>Clinical Infectious Diseases</i> , 2014, 59, 139-141.	5.8	0
65	The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis. <i>PLoS Medicine</i> , 2014, 11, e1001725.	8.4	48
66	The Survival Benefits of Antiretroviral Therapy in South Africa. <i>Journal of Infectious Diseases</i> , 2014, 209, 491-499.	4.0	32
67	Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 294-302.	2.1	7
68	A Marginal Benefit Approach for Vaccinating Influenza "Superspreaders". <i>Medical Decision Making</i> , 2014, 34, 536-549.	2.4	7
69	Cost-Effectiveness of Canine Vaccination to Prevent Human Rabies in Rural Tanzania. <i>Annals of Internal Medicine</i> , 2014, 160, 91-100.	3.9	71
70	HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy?. <i>PLoS ONE</i> , 2014, 9, e113031.	2.5	21
71	Dengue dynamics and vaccine cost-effectiveness in Brazil. <i>Vaccine</i> , 2013, 31, 3957-3961.	3.8	40
72	Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples. <i>New England Journal of Medicine</i> , 2013, 369, 1715-1725.	27.0	122

#	ARTICLE	IF	CITATIONS
73	The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial. <i>Drug and Alcohol Dependence</i> , 2013, 128, 90-97.	3.2	32
74	Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States. <i>Annals of Internal Medicine</i> , 2013, 158, 84.	3.9	117
75	Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty. <i>PLoS ONE</i> , 2013, 8, e62709.	2.5	28
76	Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness. <i>PLoS ONE</i> , 2013, 8, e84173.	2.5	32
77	The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women. <i>Clinical Infectious Diseases</i> , 2012, 54, 1504-1513.	5.8	85
78	What Is a Modest Public Health Impact?. <i>Archives of Internal Medicine</i> , 2012, 172, 521.	3.8	1
79	Impact of Program Scale and Indirect Effects on the Cost-Effectiveness of Vaccination Programs. <i>Medical Decision Making</i> , 2012, 32, 442-446.	2.4	8
80	Model Parameter Estimation and Uncertainty Analysis. <i>Medical Decision Making</i> , 2012, 32, 722-732.	2.4	564
81	Home HIV Testing: Good News but Not a Game Changer. <i>Annals of Internal Medicine</i> , 2012, 157, 744.	3.9	27
82	Conceptualizing a Model. <i>Medical Decision Making</i> , 2012, 32, 678-689.	2.4	216
83	Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. <i>Value in Health</i> , 2012, 15, 835-842.	0.3	478
84	Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. <i>Value in Health</i> , 2012, 15, 804-811.	0.3	160
85	The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results. <i>Vaccine</i> , 2011, 29, 6107-6112.	3.8	20
86	Dengue vector control strategies in an urban setting: an economic modelling assessment. <i>Lancet</i> , The, 2011, 377, 1673-1680.	13.7	118
87	Resource Utilization and Cost-Effectiveness of Counselor- vs. Provider-Based Rapid Point-of-Care HIV Screening in the Emergency Department. <i>PLoS ONE</i> , 2011, 6, e25575.	2.5	12
88	The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 26-35.	2.1	55
89	Impact of Obesity and Knee Osteoarthritis on Morbidity and Mortality in Older Americans. <i>Annals of Internal Medicine</i> , 2011, 154, 217.	3.9	201
90	Scaling Up Circumcision Programs in Southern Africa: The Potential Impact of Gender Disparities and Changes in Condom Use Behaviors on Heterosexual HIV Transmission. <i>AIDS and Behavior</i> , 2011, 15, 938-948.	2.7	22

#	ARTICLE	IF	CITATIONS
91	Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing. <i>Journal of General Internal Medicine</i> , 2011, 26, 661-667.	2.6	7
92	Medical Device Innovation "Is "Better" Good Enough?. <i>New England Journal of Medicine</i> , 2011, 365, 1464-1466.	27.0	15
93	Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis. <i>Value in Health</i> , 2010, 13, 893-902.	0.3	23
94	Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. <i>PLoS ONE</i> , 2010, 5, e13132.	2.5	93
95	Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC. <i>Clinical Infectious Diseases</i> , 2010, 51, 392-400.	5.8	100
96	Price, Performance, and the FDA Approval Process: The Example of Home HIV Testing. <i>Medical Decision Making</i> , 2010, 30, 217-223.	2.4	13
97	Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis. <i>PLoS Medicine</i> , 2010, 7, e1000382.	8.4	70
98	Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal. <i>PLoS Medicine</i> , 2009, 6, e1000173.	8.4	66
99	HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-Effectiveness. <i>Clinical Infectious Diseases</i> , 2009, 48, 806-815.	5.8	240
100	Medical decision making in patients with knee pain, meniscal tear, and osteoarthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1531-1538.	6.7	7
101	Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2009, 49, 1570-1578.	5.8	167
102	HIV Testing Rates and Outcomes in a South African Community, 2001-2006: Implications for Expanded Screening Policies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 310-316.	2.1	43
103	Cost-effectiveness of Total Knee Arthroplasty in the United States. <i>Archives of Internal Medicine</i> , 2009, 169, 1113.	3.8	476
104	When to Start Antiretroviral Therapy in Resource-Limited Settings. <i>Annals of Internal Medicine</i> , 2009, 151, 157.	3.9	113
105	Social costs of robbery and the cost-effectiveness of substance abuse treatment. <i>Health Economics (United Kingdom)</i> , 2008, 17, 927-946.	1.7	32
106	Modeling the Potential Impact of a Prescription Drug Copayment Increase on the Adult Asthmatic Medicaid Population. <i>Value in Health</i> , 2008, 11, 110-118.	0.3	4
107	Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival. <i>Journal of Infectious Diseases</i> , 2008, 197, 1324-1332.	4.0	58
108	The Effect of Antiretroviral Therapy on Secondary Transmission of HIV among Men Who Have Sex with Men. <i>Clinical Infectious Diseases</i> , 2007, 44, 1115-1122.	5.8	48

#	ARTICLE	IF	CITATIONS
109	Cost-Effectiveness of HIV Testing and Treatment in the United States. <i>Clinical Infectious Diseases</i> , 2007, 45, S248-S254.	5.8	108
110	Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 1146-1152.	2.9	105
111	Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 78-90.	2.1	24
112	Impact of Expanded HIV Screening. <i>Annals of Internal Medicine</i> , 2007, 147, 146.	3.9	0
113	Cost-effectiveness of inhaled steroids in asthma: Impact of effect on bone mineral density. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 359-366.	2.9	22
114	Expanded HIV Screening in the United States: Effect on Clinical Outcomes, HIV Transmission, and Costs. <i>Annals of Internal Medicine</i> , 2006, 145, 797.	3.9	183
115	Rapid HIV Testing at Home: Does It Solve a Problem or Create One?. <i>Annals of Internal Medicine</i> , 2006, 145, 459.	3.9	69
116	Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, S113-S118.	2.1	46
117	Forced Expiratory Volume in 1 Second Percentage Improves the Classification of Severity Among Children With Asthma. <i>Pediatrics</i> , 2006, 118, e347-e355.	2.1	89
118	Fact, Fiction, And Fairness: Resource Allocation Under The Ryan White CARE Act. <i>Health Affairs</i> , 2006, 25, 1103-1112.	5.2	12
119	The Survival Benefits of AIDS Treatment in the United States. <i>Journal of Infectious Diseases</i> , 2006, 194, 11-19.	4.0	576
120	Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced HIV Disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 69-77.	2.1	32
121	Cost-Effectiveness of HIV Screening for Incarcerated Pregnant Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 163-173.	2.1	23
122	An Asthma Policy Model. , 2005, , 659-693.		2
123	Routine human immunodeficiency virus testing: An economic evaluation of current guidelines. <i>American Journal of Medicine</i> , 2005, 118, 292-300.	1.5	108
124	Cost Advantage of Dual-Chamber Versus Single-Chamber Cardioverter-Defibrillator Implantation. <i>Journal of the American College of Cardiology</i> , 2005, 46, 850-857.	2.8	36
125	Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral. <i>Medical Decision Making</i> , 2005, 25, 321-329.	2.4	29
126	Expanded Screening for HIV in the United States – An Analysis of Cost-Effectiveness. <i>New England Journal of Medicine</i> , 2005, 352, 586-595.	27.0	504

#	ARTICLE	IF	CITATIONS
127	Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2005, 10, 41-52.	1.0	14
128	A Single Measure of FEV 1 Is Associated With Risk of Asthma Attacks in Long-term Follow-up. <i>Chest</i> , 2004, 126, 1875-1882.	0.8	133
129	Quality of life after aortic valve replacement with tissue and mechanical implants. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2004, 128, 266-272.	0.8	42
130	Association between preference-based health-related quality of life and asthma severity. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 92, 329-334.	1.0	32
131	A therapeutic HIV vaccine: how good is good enough?. <i>Vaccine</i> , 2004, 22, 4044-4053.	3.8	20
132	Economic Costs of Influenza-Related Work Absenteeism. <i>Value in Health</i> , 2003, 6, 107-115.	0.3	89
133	Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. <i>American Journal of Medicine</i> , 2003, 115, 632-641.	1.5	97
134	Impact of Site of Care, Race, and Hispanic Ethnicity on Medication Use for Childhood Asthma. <i>Pediatrics</i> , 2002, 109, e1-e1.	2.1	132
135	AIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus Infection Health Care in the United States. <i>Clinical Infectious Diseases</i> , 2002, 35, 606-610.	5.8	16
136	Treatment for Primary HIV Infection: Projecting Outcomes of Immediate, Interrupted, or Delayed Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 27-37.	2.1	34
137	The Relationship of Preventable Opportunistic Infections, HIV-1 RNA, and CD4 Cell Counts to Chronic Mortality. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 30, 421-428.	2.1	26
138	State AIDS Drug Assistance Programs. <i>Medical Care</i> , 2002, 40, 429-441.	2.4	26
139	Task Force #2 "the cost of prevention: can we afford it? Can we afford not to do it?". <i>Journal of the American College of Cardiology</i> , 2002, 40, 603-615.	2.8	21
140	A novel approach to defining the relationship between lung function and symptom status in asthma. <i>Journal of Clinical Epidemiology</i> , 2002, 55, 11-18.	5.0	19
141	Prophylaxis for Human Immunodeficiency Virus-Related <i>Pneumocystis carinii</i> Pneumonia. <i>Archives of Internal Medicine</i> , 2002, 162, 921.	3.8	59
142	Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2002, 7, 257-66.	1.0	15
143	Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2002, 7, 257-266.	1.0	37
144	The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. <i>New England Journal of Medicine</i> , 2001, 344, 824-831.	27.0	469

#	ARTICLE	IF	CITATIONS
145	Use of Health Services by Insurance Status Among Children With Asthma. <i>Medical Care</i> , 2001, 39, 1065-1074.	2.4	52
146	Model-Based Drug Evaluation in Chronic Disease: Promise, Pitfalls, and Positioning. <i>Drug Information Journal</i> , 2001, 35, 131-139.	0.5	3
147	Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2001, 32, 783-793.	5.8	26
148	Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. <i>International Journal of Epidemiology</i> , 2001, 30, 864-871.	1.9	54
149	Evaluation of Therapeutic Strategies: A New Method for Balancing Risk and Benefit. <i>Value in Health</i> , 2000, 3, 12-22.	0.3	9
150	Five Minutes with the Governor. <i>Medical Decision Making</i> , 2000, 20, 239-242.	2.4	3
151	THE COST-EFFECTIVENESS OF PROPHYLAXIS FOR <i>MYCOBACTERIUM AVIUM</i> COMPLEX IN AIDS. <i>International Journal of Technology Assessment in Health Care</i> , 1999, 15, 531-547.	0.5	9
152	Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS. <i>Pharmacoeconomics</i> , 1998, 14, 165-174.	3.3	14
153	A Monte Carlo Simulation of Advanced HIV Disease. <i>Medical Decision Making</i> , 1998, 18, S93-S105.	2.4	44
154	Organ Allocation and the Secretary Problem. <i>Medical Decision Making</i> , 1997, 17, 231-232.	2.4	1
155	Estimating CE Ratios under Second-order Uncertainty. <i>Medical Decision Making</i> , 1997, 17, 483-489.	2.4	106
156	The Cost-Effectiveness of HIV Testing. <i>Medical Decision Making</i> , 1997, 17, 490-495.	2.4	8
157	The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients. <i>Medical Decision Making</i> , 1997, 17, 373-381.	2.4	39
158	Why Training is the Key to Successful Guideline Implementation. <i>Pharmacoeconomics</i> , 1997, 12, 297-302.	3.3	7
159	Economic Evaluation of HIV Testing Among Intravenous Drug Users: An Analytic Framework and Its Application to Italy. <i>International Journal of Technology Assessment in Health Care</i> , 1996, 12, 336-357.	0.5	12
160	The FDA And Regulation Of Cost-Effectiveness Claims. <i>Health Affairs</i> , 1996, 15, 54-71.	5.2	25
161	Making Health Policy Decisions: Is Human Instinct Rational? Is Rational Choice Human?. <i>Chance</i> , 1996, 9, 34-39.	0.2	7